Nuvectis Pharma (NASDAQ:NVCT) Trading Down 5.2% – What’s Next?

Nuvectis Pharma, Inc. (NASDAQ:NVCT)’s share price was down 5.2% on Wednesday . The company traded as low as $24.27 and last traded at $24.5340. Approximately 43,397 shares changed hands during trading, a decline of 74% from the average daily volume of 166,446 shares. The stock had previously closed at $25.89.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Roth Capital raised their target price on Nuvectis Pharma from $20.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. UBS Group set a $33.00 price target on Nuvectis Pharma in a research note on Monday, July 6th. Weiss Ratings raised Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Cantor Fitzgerald assumed coverage on shares of Nuvectis Pharma in a research report on Monday. They set an “overweight” rating on the stock. Finally, Wall Street Zen upgraded shares of Nuvectis Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Nuvectis Pharma has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

Nuvectis Pharma Trading Up 0.8%

The stock has a market capitalization of $822.30 million, a price-to-earnings ratio of -19.23 and a beta of -0.26. The firm has a 50-day moving average of $20.54 and a 200 day moving average of $13.24.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). As a group, research analysts forecast that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Insider Transactions at Nuvectis Pharma

In other news, CEO Ron Bentsur bought 12,500 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was purchased at an average price of $20.00 per share, for a total transaction of $250,000.00. Following the transaction, the chief executive officer owned 3,688,424 shares in the company, valued at approximately $73,768,480. This trade represents a 0.34% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Marlio Charles Mosseri bought 50,000 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was acquired at an average price of $18.32 per share, for a total transaction of $916,000.00. Following the completion of the transaction, the insider owned 3,186,576 shares in the company, valued at $58,378,072.32. This trade represents a 1.59% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 28.55% of the company’s stock.

Institutional Trading of Nuvectis Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System lifted its stake in Nuvectis Pharma by 376.8% during the second quarter. California State Teachers Retirement System now owns 3,991 shares of the company’s stock valued at $73,000 after purchasing an additional 3,154 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of Nuvectis Pharma during the 2nd quarter valued at $5,057,000. Stonepine Capital Management LLC acquired a new stake in shares of Nuvectis Pharma during the 2nd quarter valued at $735,600,000. Bank of America Corp DE bought a new stake in shares of Nuvectis Pharma during the 2nd quarter worth $218,000. Finally, Legal & General Group Plc bought a new stake in shares of Nuvectis Pharma during the 2nd quarter worth $31,000. 96.77% of the stock is currently owned by institutional investors.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.